Literature DB >> 10459079

Is alpha-ketoisocaproyl-glutamine a suitable glutamine precursor to sustain fibroblast growth?

C Coudray-Lucas1, E Lasnier, F Renaud, F Ziegler, P Settembre, L A Cynober, O G Ekindjian.   

Abstract

BACKGROUND: Glutamine is considered an essential nutrient for cellular growth. AIM: To test the suitability of alpha-ketoisocaproyl-Gln (Kic-Gln) as a new glutamine (Gln) precursor to sustain human fibroblast growth.
METHODS: [3H] thymidine uptake into cellular DNA of human fibroblasts. Extracellular and intracellular amino acid patterns were determined with peptides and acylated compounds.
RESULTS: L-alanyl-L-glutamine (used here as a recognized Gln precursor) promoted DNA synthesis, while N-acetyl-L-glutamine (used here as a negative control since it is known to be a poor Gln precursor) and alpha-ketoisocaproyl-glutamine had no effect. Alanyl-glutamine progressively gave rise to free glutamine in the growth medium. In contrast, glutamine supplied in acylated form was poorly available and did not appear in free form in the medium. In addition, only alanyl-glutamine increased intracellular glutamine and glutamate levels. In contrast, Kic-Gln was able to sustain net protein synthesis as judged by total protein content and reduced intracellular levels of most essential amino acids.
CONCLUSION: Kic-Gln appears to be a poor extra-cellular precursor of Gln to sustain cell growth. Copyright 1999 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10459079     DOI: 10.1016/s0261-5614(99)80046-6

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  2 in total

1.  A randomised controlled trial evaluating the use of enteral nutritional supplements postoperatively in malnourished surgical patients.

Authors:  A H Beattie; A T Prach; J P Baxter; C R Pennington
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

2.  Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: a randomised controlled trial.

Authors:  M C Steiner; R L Barton; S J Singh; M D L Morgan
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.